Spine surgeons validated clinical and economic benefits of an entirely synthetic solution in lateral lumbar fusions
SAN DIEGO , July 26, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the results of the study "Can a bioactive interbody device reduce the cost burden of achieving lateral lumbar fusion?" in the Journal of Neurosurgery: Spine. The study validates entirely synthetic solutions featuring porous interbody implants and bone graft substitute having clinical and economic advantages versus traditional, non-porous interbody implants with premium-priced biologics.
"Having clinically-backed Advanced Materials Science options, from synthetic biologics to porous interbody implants, gives surgeons stronger procedural offerings across the entire spine," said Massimo Calafiore , Chief Commercial Officer at NuVasive. "NuVasive leads with a focus on disruptive innovation—providing not only procedures that are better clinically for both patients and surgeons, but also less expensive for the hospitals we partner with."
The multi-center, retrospective study consisted of 90 patients who underwent lateral lumbar interbody fusions with the combination of a synthetic bone graft substitute, Attrax ® Putty, and a porous titanium interbody implant, Modulus® XLIF®. The study found that the use of synthetic biologics and interbody implants with advanced surface technologies resulted in a high rate of effective fusion on CT imaging at 12 months with complete bone bridging in 97.8% of patients, despite the use of a small volume of lower-cost biological material.1 Often, surgeons rely on premium-priced biologics like recombinant human bone morphogenetic protein-2 (rhBMP-2) to support bone through-growth during a patient's recovery phase.
Attrax Putty is the first and only synthetic bone graft with U.S. Food and Drug Administration indications for thoracolumbar interbody fusion and is also a relatively inexpensive biologic option.1 Modulus XLIF, part of the Advanced Materials Science® portfolio, provides a fully porous architecture and favorable environment for bone in-growth,2 supporting the less invasive XLIF procedure that is designed to be clinically and economically beneficial.
"I am excited to see outcomes that have been traditionally associated with BMP achieved with cost-effective biologics used in porous interbody cage technology," said Robert Eastlack , M.D., orthopedic spine surgeon at Scripps Health in San Diego and board member of the San Diego Spine Foundation. "The results of this study have created lasting change in our practices, presented huge cost savings and showed significant benefits to the patients."
The results of this study build upon the extensive clinical evidence validating Modulus interbody technology, Attrax Putty and the broader X360 portfolio. Studies show that:
90 patients treated at 136 thoracolumbar levels with Modulus XLIF and Attrax Putty showed high rates of success and low rates of complications.1
In the only Level I randomized controlled trial of a synthetic bone graft substitute in instrumented posterolateral fusion, Attrax Putty demonstrated non-inferiority to autograft.3
When used in combination with single-position surgery, Modulus XLIF and Attrax Putty could substantially improve perioperative economics to the hospital through decreased operative time, while meeting postoperative alignment and clinical outcome goals.4-7
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
1 Malone H, Mundis Jr., GM, Collier, M, et al. Can a bioactive interbody device reduce the cost burden of achieving lateral lumbar fusion? J Neurosurg Spine. Published online June 3, 2022 ; DOI: 10.3171/2022.4.SPINE211070. 2 Fogel G, Martin N, Lynch K, et al. Subsidence and fusion performance of a 3D-printed porous interbody cage with stress-optimized body lattice and microporous endplates - a comprehensive mechanical and biological analysis. Spine J 2022;22:1028-37. 3 Lehr AM, Oner FC, Delawi D, et al. Efficacy of a Standalone microporous ceramic vs. autograft in instrumented posterolateral spinal fusion; a multicenter, randomized, intra-patient controlled, non-inferiority trial. Spine 2020;45(14):944-51. 4 Blizzard DJ, Thomas JA. MIS Single-position lateral and oblique lateral lumbar interbody fusion and bilateral pedicle screw fixation: feasibility and perioperative results. Spine 2017 Jul 12. [Epub ahead of print] 5 Rhee JW, Petteys RJ, Anaizi AN, et al. Prospective evaluation of 1-year outcomes in single-level percutaneous lumbar trans facet screw fixation in the lateral decubitus position following lateral trans psoas interbody fusion. Eur Spine J 2015;24(11):2546-54. 6 Thomas JA. Single-position lateral lumbar interbody fusion and percutaneous pedicle screw fixation allows for adequate correction of spinal sagittal imbalance. Paper presented at Society for Minimally Invasive Spine Surgery (SMISS) 2016 Annual Forum. Las Vegas, NV , USA. 7 Voyadzis JM, Anaizi AN. Minimally invasive lumbar trans facet screw fixation in the lateral decubitus position after extreme lateral interbody fusion: a technique and feasibility study. J Spinal Disord Tech 2013;26(2):98-106.
View original content to download multimedia:https://www.prnewswire.com/news-releases/clinical-study-validates-nuvasive-porous-interbody-implant-and-synthetic-bone-graft-substitute-as-cost-effective-solution-for-lateral-lumbar-interbody-fusions-301592968.html
SIGA Technologies, maker of the only available monkeypox treatment, is working to ramp up manufacturing for broader global distribution.
We just can't get a break from COVID. While things were inching closer towards normalcy, cases are rising again thanks to the latest dominant variant BA.5, which experts say is the most contagious COVID strain yet. Although the virus affects everyone differently, there are symptoms to watch out for that indicate you've had COVID and Eat This, Not That! Health spoke with Dr. Mark Fischer, Regional Medical Director at International SOS who explains what to know about BA.5 and symptoms to watch out
Monkeypox has spread across multiple countries, including the U.S., where the Centers for Disease Control and Prevention (CDC) has confirmed almost 5,000 cases since May. While reminiscent of the beginning of the COVID-19 pandemic, this viral disease spreads differently. We all remember masking up, wearing gloves, and waiting in line to get into the grocery store in 2020, but will we have to do that again because of this virus?Experts at the CDC and others say monkeypox spreads mostly through cl
'We need vaccines with longer duration and greater breadth of protection,' said Dr. David Kessler, chief science officer for the White House’s COVID-19 response team.
A federal court ruling has dealt a blow to Bausch Health by appearing to clear the way for generic competition for the company’s drug Xifaxan. Bausch Health stock (ticker: BHC) plummeted more than 50% Thursday morning on the news, and trading of the shares was halted. In 2020, Bausch Health Ireland and Salix Pharmaceuticals sued Norwich Pharmaceuticals in 2020 for patent infringement, regarding Norwich’s plans to bring a generic version of Xifaxan to market before its patents had expired, according to a Bloomberg Law report.
With growing concerns that the monkeypox outbreak could turn into another pandemic, local health offices have been flooded with requests for the monkeypox vaccine. According to the Centers for Disease Control and Prevention, there have been just 330 cases here in Georgia as of July 29.
The highly contagious BA.5 subvariant is causing a nationwide spike in cases, and experts believe the numbers might actually be higher thanks to at-home testing. But even without accurate data, there is no doubt a surge is happening. "You don't have to count every raindrop to know it's raining," says Dr. Joseph Kanter, Louisiana's state health officer and medical director. "And it's pouring right now." Here are five signs of BA.5 that are easy to miss, according to experts. Read on—and to ensure
The company had said it was in talks with the FDA about seeking early approval, but Wall Street analysts thought the agency would make it wait to apply.
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?
Compared with the earlier Omicron BA.2 subvariant, currently dominant Omicron BA.5 is linked with higher odds of causing a second SARS-COV-2 infection regardless of vaccination status, a study from Portugal suggests. Further, they found, in infected heart muscle cells only the SARS-CoV-2 spike interacted with so-called TLR4 proteins (Toll-like receptor-4) that recognize invaders and trigger inflammatory responses.
AstraZeneca's Covid-19 antibody drug slashes the risk of new variants emerging, the company said, as Britain faces mounting pressure to follow other Western nations in ordering doses.
Is Pfizer stock a sell after Wall Street reduced its expectations for 2022 sales and profit? Is PFE stock a sell right now?
The Biden administration said it would spend $1.74 billion to buy 66 million doses of Moderna updated Covid-19 vaccine, as well as the option to purchase up to 234 million additional doses, as part of a fall booster campaign. The deal Friday, which follows an agreement to buy 105 million doses of updated vaccines from Pfizer and partner BioNTech SE is expected to give the federal government enough shots for a booster push as early as September. Under the latest deal, the U.S. government has the option to buy up to an additional 234 million doses from Moderna.
If a decision is made to choose abortion, it is because what is lost to that woman and her family is balanced against what is gained.
The 300 vaccines that were allocated for DeKalb County are already spoken for.
Dementia is a brain disorder that affects an estimated 55 million people worldwide according to the World Health Organization. The condition is becoming more common and while age is a leading risk factor, people under 65 can also have dementia, which causes memory loss, mood changes, getting lost in familiar places and more. Being aware of other risk factors like lack of sleep, poor diet, social isolation and not enough exercise can make a difference, but so does knowing your blood type, accordi
As a new study confirms drinking too much really does make you look older, Lisa Salmon looks into other lifestyle factors that may contribute too.
CHICAGO (Reuters) -People at high risk of severe disease who have yet to get a second COVID-19 booster should not wait for next-generation, Omicron-targeted vaccines expected in the fall, five vaccine experts told Reuters. In many countries, including the United States, the BA.5 Omicron subvariant of the virus is surging, but current vaccines continue to offer protection against hospitalization for severe disease and death. And, as the virus evolves, it is not known what version will be widely circulating in the fall or whether new vaccines - expected to target BA.4/5 in the United States and BA.1 in Europe - will be a good match.
With monkeypox cases on the rise across the country, there are now more than 110 confirmed cases of the disease here in Maryland, according to the latest data released by the Centers for Disease Control and Prevention.
Story at a glance For the study, more than 501,000 people with an average age of 56 from a U.K database filled out questionnaires asking how often they participated in various physical activities, household and job-related tasks and mental activities, like social visits. Participants reported their family history for dementia to help researchers narrow down…